SA PRO
Free Account
Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 72% recommend buying.

Consensus Rating
Buy
18 analysts·Moderate coverage
72%
Rating Distribution
Strong Buy
00%
Buy
1372%
Hold
528%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 10% higher.

Bear Case
$35.00
-51%
Consensus
$79.11
+10%
Bull Case
$110.00
+52%
Price Range18 analysts
Low
Consensus
High
$35.00
$110.00
Current Target
Current Price
$72.14
Upside to Target
$6.97

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.27(11 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev-25.86%
EPS—
FY2028
Rev+88.70%
EPS—
FY2029
Rev+52.98%
EPS—

Earnings Surprises

Beat rate:17%(2/12 quarters)
Avg surprise:+204.3%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Robert W. Baird
Morgan Stanley on Arrowhead Pharma (ARWR): 'we are encouraged by the on track progress for the ARO-DIMER-PA program'
Target:$81.00
+20.9%from $67.02
Jan 21, 2026H.C. Wainwright
Arrowhead price target raised to $100 from $85 at H.C. Wainwright
Target:$100.00
+45.3%from $68.80
Jan 13, 2026UBS
'Arrowhead Pharma (ARWR) Raises $930 Million to Launch Redemplo'; PT Raised at Piper Sandler
Target:$110.00
+61.7%from $68.03
Jan 13, 2026Piper Sandler
Arrowhead price target raised to $110 from $100 at Piper Sandler
Target:$110.00
+66.8%from $65.93
Jan 7, 2026Morgan Stanley
Arrowhead price target raised to $81 from $48 at Morgan Stanley
Target:$81.00
+14.4%from $70.81
Jan 7, 2026Chardan Capital
Arrowhead price target raised to $80 from $60 at Chardan
Target:$80.00
+13.0%from $70.81
Jan 2, 2026Tudor Pickering
Arrowhead Pharma (ARWR) PT Raised at Bernstein Ahead of Obesity Data Update
Target:$35.00
-47.3%from $66.39
Dec 31, 2025Bernstein
Arrowhead price target raised to $35 from $17 at Bernstein
Target:$35.00
-48.0%from $67.25
Dec 17, 2025Piper Sandler
Arrowhead price target raised to $100 from $70 at Piper Sandler
Target:$100.00
+54.7%from $64.66
Dec 11, 2025RBC Capital
Arrowhead price target raised to $80 from $52 at RBC Capital
Target:$80.00
+16.1%from $68.91
Dec 2, 2025H.C. Wainwright
Arrowhead price target raised to $85 from $80 at H.C. Wainwright
Target:$85.00
+51.1%from $56.25
Nov 26, 2025Morgan Stanley
Arrowhead price target raised to $48 from $45 at Morgan Stanley
Target:$48.00
+2.6%from $46.79
Nov 29, 2024Bernstein
Arrowhead Pharma (ARWR) PT Lowered to $24 at Bernstein SocGen Group
Target:$24.00
-7.0%from $25.81
Nov 27, 2024Loop Capital Markets
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
Target:$60.00
+365.1%from $12.90
Sep 3, 2024Citigroup
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
Target:$27.00
+17.9%from $22.91
Jul 5, 2024H.C. Wainwright
Arrowhead Pharma (ARWR) PT Lowered to $60 at H.C. Wainwright
Target:$60.00
+369.9%from $12.77
Jun 5, 2024Goldman Sachs
Goldman Sachs Starts Arrowhead Pharma (ARWR) at Neutral
Target:$31.00
+22.6%from $25.29
May 30, 2024RBC Capital
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
Target:$50.00
+337.4%from $11.43
Feb 7, 2023RBC Capital
RBC Capital Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $77
Target:$77.00
+368.1%from $16.45
Feb 7, 2023Piper Sandler
Piper Sandler Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $52
Target:$52.00
+55.2%from $33.51
Dec 6, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $90
Target:$90.00
+471.4%from $15.75
Nov 29, 2022Jefferies
Jefferies Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $75
Target:$75.00
+400.3%from $14.99
Nov 29, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Arrowhead Pharmaceuticals, Lowers Price Target to $37
Target:$37.00
+32.1%from $28.00
Nov 29, 2022Leerink Partners
SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Lowers Price Target to $31
Target:$31.00
+10.7%from $28.00
Jan 19, 2022Goldman Sachs
Arrowhead Pharmaceuticals Stock (ARWR): $85 Price Target From Goldman Sachs
Target:$85.00
+58.0%from $53.79

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance